Isomorphic Labs raises €4.5 billion to speed AI drug discovery toward clinical trials
Isomorphic Labs, spun out of Google's DeepMind, has secured €4.5 billion ($5 billion) in a Series C funding round co-led by Greenoaks and Sequoia Capital, with significant investment from Alphabet and Andreessen Horowitz. The funding aims to accelerate AI-driven scientific breakthroughs in medicine design and development, with plans to advance promising drug candidates into clinical testing phases.
Why it matters
This funding boost enables Isomorphic Labs to rapidly develop AI-discovered drugs, potentially shortening the timeline for new treatments to reach patients and impacting healthcare innovation worldwide.
Discussion
Loading discussion…
Anyone can vote. Approved members can comment. Log in